Results 231 to 240 of about 55,959 (291)

ECG Markers of Positive Drug Challenge With Ajmaline in Patients With Brugada Syndrome

Annals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.
A prominent S‐wave in lead II on a nondiagnostic baseline ECG is a powerful predictor for unmasking Brugada syndrome during an ajmaline challenge. This subtle sign enhances patient selection for provocation testing and aids in risk stratification, particularly in familial screening.
Erol Tülümen, Mathieu Kruska, Sara Wuerfel, Maximilian Kohl, Volker Liebe, Ibrahim Akin, Juergen Kuschyk, Daniel Duerschmied, Martin Borggrefe, Boris Rudic   +9 more
wiley   +1 more source

QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy.

Journal of Clinical Endocrinology and Metabolism, 1987
J. Kahn, J. Sisson, A. Vinik
semanticscholar   +1 more source

Left Ventricular Ejection Fraction and Incident Cardiac Conduction Dysfunction: Exploring the Mediating Effects of Electrophysiological Parameters

Annals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.
Left ventricular ejection fraction (LVEF) and incident cardiac conduction dysfunction (CCD). Models were adjusted for age, waist‐to‐hip ratio, hypertension, diabetes mellitus, ischemic heart diseases, atrial fibrillation, left ventricular myocardial mass, left ventricular end‐diastolic volume, PQ interval, QRS duration and corrected QT interval ...
Qie Zhang, Feilong Zhang, Yuhao Hu, Jinfeng Wang, Xinlin Yang, Zhou Du, Yuting Chen, Jiran Shen, Ronghui Yu   +8 more
wiley   +1 more source

Sex Hormones and Repolarization Dynamics During the Menstrual Cycle in Women Treated With QT‐Prolonging Drugs

Annals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.
Sex hormones significantly influence ventricular repolarization in women treated with QT‐prolonging drugs, with estrogen prolonging and progesterone/testosterone shortening QT measures. These findings highlight a hormonal mechanism for sex‐specific arrhythmia risk and support closer monitoring of reproductive‐age women receiving QT‐prolonging therapies.
Aneliya San, Ilan Goldenberg, Arwa Younis, Kris Cutter, Scott McNitt, Nona Sotoodehnia, Peter J. Kudenchuk, Thomas D. Rea, Dan E. Arking, Bronislava Polonsky, Wojciech Zareba, Mehmet Kemal Aktaş   +11 more
wiley   +1 more source

Low and High Pressor Doses of Ang II Lead to Two Distinct Phenotypes of Hypertensive Heart Disease in Mice

APMIS, Volume 134, Issue 1, January 2026.
ABSTRACT Hypertension is a major contributor to cardiovascular diseases, being the most common comorbidity and the biggest risk factor in heart failure with preserved ejection fraction. Angiotensin II (Ang II) is a known hypertension and heart failure inducer in mice, but its role in the causality in phenotype development remains unclear.
Diana Törmä, Tuisku Suoranta, Mimmi Rinta‐Harri, Jarkko Hytönen, Seppo Ylä‐Herttuala, Anna‐Kaisa Ruotsalainen   +5 more
wiley   +1 more source

Assessment Of Pharmacist-Driven QT Interval Prolongation In Cardiac Patients: Application Of Framingham's Heart Rate Corrected QT Interval Formula And The Tisdale Risk Score

Ahmad Ullah Humza, Sadia Ghousia Baig, Zafar Iqbal, Gul Sama, Ahmed Imran, Asma Hamza   +5 more
openalex   +1 more source

An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk

British Journal of Pharmacology, 2010
C. Pollard, N. A. Gerges, M. Bridgland-Taylor, A. Easter, T. Hammond, J. Valentin   +5 more
semanticscholar   +1 more source

Safety, Tolerability, and Pharmacokinetics of Single Doses of ABBV‐916, an Anti‐Amyloid Antibody, in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Amyloid‐beta (Aβ) plaque brain clearance is one of the promising disease‐modifying treatment approaches to slow cognitive decline in Alzheimer's disease (AD). ABBV‐916, an anti‐amyloid antibody, was being developed as an early AD disease‐modifying treatment.
Sagar S. Bachhav, Hana Florian, Joey Boiser, Yamin Wang, Dee‐Dee Shiller, Ulrike Graab, Shau Yu Lynch, Ole Graff, Hao Xiong   +8 more
wiley   +1 more source

Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation.

Oxid Med Cell Longev, 2021
Zhang J, Luo D, Li F, Li Z, Gao X, Qiao J, Wu L, Li M.   +7 more
europepmc   +1 more source